Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Balducci

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
Neural Regeneration Research|August 14, 2025
Role of prion protein in mediating the synaptotoxic effects of tau oligomers: Implications for Alzheimer's disease and related tauopathiesRoberto Chiesa, Luana Fioriti, Gianluigi Forloni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 17, 2021
A critical appraisal of tau-targeting therapies for primary and secondary tauopathiesBruno P Imbimbo, Stefania Ippati, Mark Watling, et al.
Neural Regeneration Research|July 8, 2022
Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-β storyBruno P Imbimbo, Claudia Balducci, Stefania Ippati, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 2016
Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseasesGianluigi Forloni, Vladimiro Artuso, Pietro La Vitola, et al.
Progress in Molecular Biology and Translational Science|January 17, 2021
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insightGianluigi Forloni, Pietro La Vitola, Milica Cerovic, et al.
Pharmacological Research|August 8, 2022
Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?Bruno P Imbimbo, Stefania Ippati, Camillo Imbimbo, et al.
Expert Opinion on Drug Discovery|March 3, 2021
Accelerating Alzheimer's disease drug discovery and development: what's the way forward?Bruno P Imbimbo, Stefania Ippati, Mark Watling, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 30, 2005
Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in ratsMirjana Carli, Marta Baviera, Roberto W Invernizzi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 6, 2004
The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortexCarli Mirjana, Marta Baviera, Roberto W Invernizzi, et al.
Ageing Research Reviews|September 24, 2021
Hippuric acid: Could became a barometer for frailty and geriatric syndromes?Giulia De Simone, Claudia Balducci, Gianluigi Forloni, et al.
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
Neural Regeneration Research|August 14, 2025
Role of prion protein in mediating the synaptotoxic effects of tau oligomers: Implications for Alzheimer's disease and related tauopathiesRoberto Chiesa, Luana Fioriti, Gianluigi Forloni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 17, 2021
A critical appraisal of tau-targeting therapies for primary and secondary tauopathiesBruno P Imbimbo, Stefania Ippati, Mark Watling, et al.
Neural Regeneration Research|July 8, 2022
Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-β storyBruno P Imbimbo, Claudia Balducci, Stefania Ippati, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 2016
Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseasesGianluigi Forloni, Vladimiro Artuso, Pietro La Vitola, et al.
Progress in Molecular Biology and Translational Science|January 17, 2021
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insightGianluigi Forloni, Pietro La Vitola, Milica Cerovic, et al.
Pharmacological Research|August 8, 2022
Should we lower or raise levels of amyloid-β in the brains of Alzheimer patients?Bruno P Imbimbo, Stefania Ippati, Camillo Imbimbo, et al.
Expert Opinion on Drug Discovery|March 3, 2021
Accelerating Alzheimer's disease drug discovery and development: what's the way forward?Bruno P Imbimbo, Stefania Ippati, Mark Watling, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 30, 2005
Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in ratsMirjana Carli, Marta Baviera, Roberto W Invernizzi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 6, 2004
The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortexCarli Mirjana, Marta Baviera, Roberto W Invernizzi, et al.
Ageing Research Reviews|September 24, 2021
Hippuric acid: Could became a barometer for frailty and geriatric syndromes?Giulia De Simone, Claudia Balducci, Gianluigi Forloni, et al.
Pageof 8